

[18F]-tetrafluoroborate in patients with primary thyroid cancer or salivary cancer

Submission date 19/11/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/11/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 26/10/2022	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-using-pet-ct-scans-to-detect-thyroid-cancer-and-salivary-gland-cancer>

Contact information

Type(s)

Scientific

Contact name

Dr Maite Jauregui-Osoro

Contact details

King's College London
The Rayne Institute
4th Floor Lambeth Wing
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Additional identifiers

Clinical Trials Information System (CTIS)

2014-001925-33

Protocol serial number

19094

Study information

Scientific Title

A phase I trial of [18F]-tetrafluoroborate in patients with primary thyroid cancer or salivary cancer to study biodistribution and uptake in tumours and normal NIS expressing tissue

Acronym

BF4

Study objectives

The aim of this study is to investigate whether tetrafluoroborate has any side effects and if it specifically targets cancers that express the hNIS transporter.

Ethics approval required

Old ethics approval format

Ethics approval(s)

London - Surrey Borders Research Ethics Committee, 29/12/2014, ref: 14/LO/1247

Study design

Non-randomised; Interventional; Design type: Not specified

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Head and Neck Cancer; Disease: Head and Neck

Interventions

Cannula inserted into each arm for the administration of the radioactive material and the taking of blood samples.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Tetrafluoroborate

Primary outcome(s)

To assess the biodistribution of [18F]tetrafluoroborate in vivo

Key secondary outcome(s)

Not provided at time of registration

Completion date

02/08/2017

Eligibility

Key inclusion criteria

1. Aged 18-80 years
2. Women of childbearing potential must have documented negative pregnancy test on day 1, prior to (18F)BF4-administration
3. Diagnosis of a malignancy of the thyroid or a malignancy of a salivary gland
4. All patients have to be suitable for surgical treatment as part of their normal management
5. Able to comply with treatment plans, scheduled visits, all study PET imaging and follow-up
6. Willing to give informed consent
7. Not be taking thyroid medication or iodine containing medication

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

80 years

Sex

All

Total final enrolment

5

Key exclusion criteria

1. Previous ionising radiation exposure for research purposes or exposure to any previous experimental medicine that might affect the uptake of BF4 would exclude the patient from this ionising radiation study
2. Patients without adequate understanding of written or spoken English would not be able to participate in this study as translation of the patient information sheet will not be possible
3. Any prior treatment for the thyroid or salivary gland tumours
4. Pregnancy or lactation
5. Any other problems that may make the patient unable to tolerate the PET scans or translational biopsies
6. Ingestion of iodine containing medication (eg amiodarone) within preceding 12 months, administration of iv contrast media within 6 months or thyroid hormones within 2 months

Date of first enrolment

14/09/2015

Date of final enrolment

02/08/2017

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

St Thomas' Hospital

The Rayne Institute

4th Floor Lambeth Wing

Westminster Bridge Road

London

United Kingdom

SE1 7EH

Sponsor information

Organisation

King's College London

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

University/education

Funder Name

King's Health Partners

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	06/04/2017	07/08/2020	Yes	No
HRA research summary	Participant information sheet		28/06/2023	No	No
Participant information sheet		11/11/2025	11/11/2025	No	Yes
Plain English results		26/07/2021	29/07/2021	No	Yes